Company news

Agenus Inc. news in 2020

Agenus Inc.'s news releases, calls and decks from 2020, newest first.

View company

Completion of Balstilimab BLA Filing Extended To 1H2021

December 2, 2020

Agenus Launches Phase 2 Trial Expansion in Colon Cancer for AGEN1181 in Combination with Balstilimab

November 30, 2020

An Agenus-discovered first-in-class ILT4 antibody, MK-4830, enters Phase 2

November 9, 2020

Agenus Doses First COVID-19 Patient with iNKT Cell Therapy

November 1, 2020

Susan Hirsch Joins Agenus’ Board of Directors

October 12, 2020

Agenus Initiates Rolling BLA Submission of Balstilimab for Recurrent/Metastatic Cervical Cancer

September 17, 2020

Paul Clark Joins Agenus Board of Directors

August 30, 2020

Agenus Announces ESMO Oral Presentation of Two Clinical Trials of Balstilimab Alone and in Combination with Zalifrelimab in Recurrent or Metastatic Cervical Cancer

August 25, 2020

Agenus Provides R&D Update & Second Quarter Financial Report

August 5, 2020

Agenus First Quarter Results and Update

May 6, 2020

Agenus to Report First Quarter 2020 Financial Results on May 7, 2020 and Host Conference Call and Webcast

April 27, 2020

Agenus Receives Fast Track Designation for Balstilimab in Advanced Cervical Cancer

April 6, 2020

Agenus to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020 with Conference Call and Webcast

March 2, 2020

Agenus Announces Positive Interim Data from Balstilimab and Zalifrelimab Clinical Trials in Second-Line Cervical Cancer

February 19, 2020

Agenus Announces Investor Day on February 20, 2020

February 5, 2020

Agenus Commences Phase 1 trial with AGEN1223

January 7, 2020

Decks in 2020